No data to show
OTCM
CYAN
Market cap2mUSD
Aug 01, Last price
0.37USD
1D
0.00%
1Q
-13.95%
Jan 2017
-91.40%
Name
Cyanotech Corp
Chart & Performance
P/E
—
P/S
0.12
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.34%
Rev. gr., 5y
-5.24%
Revenues
23m
-0.46%
Net income
-5m
L+53.11%
CFO
-455k
L-78.33%
Earnings
Aug 05, 2025
Profile
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae worldwide. The company's products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant to enhance skin, and to support eye, joint and immune health, as well as used as a human dietary supplement and dietary ingredient; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement, which is used for extra energy, strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. It also provides contract extraction services. The company sells its products through distributors, retailers, and online channels; direct to consumers; and in bulk form to manufacturers, formulators, and distributors in the health foods, nutraceuticals, and dietary supplement markets. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
| Income | |||||||||
Revenues | 23,071 -0.46% | 23,178 -35.56% | |||||||
Cost of revenue | 27,663 | 26,098 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (4,592) | (2,920) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 7 | 18 | |||||||
Tax Rate | |||||||||
NOPAT | (4,599) | (2,938) | |||||||
Net income | (5,267) 53.11% | (3,440) -259.70% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 388 | (10) | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 6,160 | 5,892 | |||||||
Long-term debt | 9,018 | 10,033 | |||||||
Deferred revenue | (2) | ||||||||
Other long-term liabilities | 3 | ||||||||
Net debt | 14,471 | 14,951 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (455) | (2,100) | |||||||
CAPEX | (1,068) | ||||||||
Cash from investing activities | (381) | (1,068) | |||||||
Cash from financing activities | 569 | 1,553 | |||||||
FCF | (29) | (3,982) | |||||||
| Balance | |||||||||
Cash | 707 | 974 | |||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | (22,901) | (17,509) | |||||||
Invested Capital | 45,619 | 45,024 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 6,531 | 6,244 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (2,511) | (825) | |||||||
EV/EBITDA | |||||||||
Interest | 668 | 502 | |||||||
Interest/NOPBT | |||||||||